Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.61 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265381 | 1.00 | SLC6A4 (0.61) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL12367661 | 0.88 | SLC6A4 (0.56) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL2264717 | 0.88 | SLC6A4 (0.67) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL2264721 | 0.88 | SLC6A4 (0.67) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL2265802 | 0.84 | SLC6A4 (0.59) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL2265809 | 0.84 | SLC6A4 (0.59) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL1121788 | 0.80 | SLC6A4 (0.80) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1121787 | 0.80 | SLC6A4 (0.80) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL12367635 | 0.79 | SLC6A4 (0.61) | SLC6A4PTPRASLC6A2SLC6A3CYP2C19 | |
| SCHEMBL1122249 | 0.78 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010527-B1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2013-08-14 | — | — | EP | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | SLC6A4 336/4885PTPRA 2508/4885SLC6A2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.